Research programme: CD47/SIRPalpha pathway modulators - Sanquin/Synthon

Drug Profile

Research programme: CD47/SIRPalpha pathway modulators - Sanquin/Synthon

Alternative Names: CD47 antigen/SIRPalpha protein modulators; CD47-SIRPα modulators

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Synthon
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fragments; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action CD47 antigen modulators; SIRPA protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 Mar 2017 Sanquin Blood Supply Foundation exclusively licenses US 9 352 037 patent and its foreign family members, EP 2 282 772 patents to Synthon Biopharmaceuticals
  • 02 Mar 2017 Early research in Cancer in Netherlands (Parenteral) before March 2017
  • 02 Mar 2017 Synthon Biopharmaceuticals and Sanquin Blood Supply Foundation enter into a licence and collaboration agreement to develop immuno-oncology therapeutics modulating the CD47-SIRPα pathway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top